Dental decay due to xerostomia and nystatin.
Phillips
Scott M
SM
Department of Care Planning and Restorative Sciences, School of Dentistry, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA. smphillips@sod.umsmed.edu
Dellinger
Tracy M
TM
D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy / Q000382:microbiology; D003731:Dental Caries / Q000139:chemically induced / Q000209:etiology*; D005079:Excipients / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009761:Nystatin / Q000008:administration & dosage* / Q000627:therapeutic use; D013395:Sucrose / Q000008:administration & dosage / Q000009:adverse effects*; D013535:Suspensions; D014133:Tracheal Diseases / Q000188:drug therapy / Q000382:microbiology; D014987:Xerostomia / Q000150:complications*
D000935:Antifungal Agents; D005079:Excipients; D013535:Suspensions; D009761:Nystatin; D013395:Sucrose